Primary central nervous system lymphoma

This study tests whether adding the drug ibrutinib to standard chemotherapy can better control primary central nervous system lymphoma (PCNSL) in people who are not eligible for a stem cell transplant. About 30 adults aged 65 or older or with other health issues will receive the …

This early-phase trial is testing a new type of CAR T cell therapy called Azer-cel, which is made from healthy donor cells rather than the patient's own cells. It aims to treat adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and relat…

This phase 3 trial is testing whether the oral targeted drug tirabrutinib works better than a standard combination of rituximab and temozolomide for people with relapsed or refractory primary central nervous system lymphoma (PCNSL). About 132 participants will be randomly assigne…

This study is testing a new type of immunotherapy called liso-cel (Breyanzi) as the first treatment for primary central nervous system lymphoma (PCNSL), a rare brain cancer. The trial is for 65 adults who cannot have a stem cell transplant. Liso-cel is made from the patient's own…

This early-phase study tests a new type of CAR-T cell therapy for people with certain blood cancers (like leukemia and lymphoma) that have not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack cancer cells. The main goa…

This trial is testing whether adding a targeted drug called orelabrutinib to standard chemotherapy can improve outcomes for people newly diagnosed with primary central nervous system lymphoma, a rare type of brain cancer. About 215 participants will be randomly assigned to one of…

This early-phase trial tests whether a combination of two drugs (loncastuximab tesirine and rituximab) given after precise radiation to the brain is safe and effective for central nervous system lymphoma. The study enrolls 12 adults whose lymphoma has returned or who cannot recei…

This trial is testing whether combining a short course of focused radiation with three drugs—GM-CSF, pomalidomide, and glofitamab—can effectively treat newly diagnosed primary central nervous system diffuse large B-cell lymphoma (PCNSL), a rare and aggressive cancer of the brain …

This phase 2 trial is testing whether paxalisib (GDC-0084), an oral drug taken daily, can shrink or control tumors in people with recurrent or refractory primary central nervous system lymphoma (PCNSL) — a rare type of non-Hodgkin lymphoma that starts in the brain or spinal cord.…

This trial is testing whether taking tirabrutinib daily can help people with primary central nervous system lymphoma (PCNSL) stay in remission longer after their initial chemotherapy has worked. Participants who have achieved complete remission will be randomly assigned to receiv…

This early-phase study tests whether combining two drugs, epcoritamab and ibrutinib, is safe for people whose central nervous system lymphoma has come back or not responded to treatment. About 26 adults with this rare cancer will receive the drug combination. The main goal is to …

This trial investigates a combination of two drugs—tafasitamab, an antibody given by IV, and lenalidomide, an oral medication—for people with relapsed central nervous system (CNS) lymphoma. The study includes up to 35 participants and is the first to test this antibody in CNS lym…

This phase 2 trial tests a personalized cell therapy called zamtocabtagene autoleucel (MB-CART2019.1) for people with B cell lymphomas that have come back or not responded to standard treatments. Participants receive their own immune cells that have been genetically modified to r…

This early-phase study tests a new type of immunotherapy called CD19x22 CAR T cells for teenagers and adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to attack two targets on cancer …

This early-phase study tests a new drug called NX-5948 in adults with advanced B-cell blood cancers (like certain leukemias and lymphomas) that have not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The main goa…

This study tests a new drug called epcoritamab, given with two other drugs (lenalidomide and rituximab), for people whose primary CNS lymphoma has returned or stopped responding to treatment. The goal is to see if this combination can shrink or control the cancer. About 60 adults…

This early-phase study tests a personalized cell therapy called MB-CART19.1 for people with central nervous system lymphoma (CNSL) that has returned or not responded to prior treatments. The therapy uses the patient's own immune cells, modified to attack the cancer, and is made o…

This early-phase study tests a new drug called [90Y]Y-PentixaTher for people with central nervous system (CNS) lymphoma that has come back or not responded to standard treatments. The drug delivers radiation directly to cancer cells. About 15 participants will receive one intrave…

This phase 2 trial tests a combination of four drugs—pirtobrutinib, sintilimab, rituximab, and high-dose methotrexate—as a first treatment for adults with newly diagnosed primary central nervous system lymphoma (PCNSL). About 77 participants will choose either this experimental c…

This early-phase trial tests a new approach to treat central nervous system (CNS) lymphoma by injecting specially engineered immune cells (CAR T cells) directly into the fluid surrounding the brain. The study involves 20 participants and aims to find the safest dose while monitor…

This study tests a combination of five drugs (R-PMDT) in 33 people newly diagnosed with primary central nervous system lymphoma, a rare brain cancer. The goal is to see how many patients' tumors shrink or disappear after six cycles of treatment. Researchers will also track how lo…

This early-stage trial tests whether adding the targeted drug zanubrutinib to a standard chemotherapy regimen (Pola-R-CHP plus high-dose methotrexate) is safe for people with large B-cell lymphoma that has spread to the central nervous system (brain or spinal cord). About 20 adul…

This study tests a powerful two-step approach for people with a fast-growing type of lymphoma that has not responded to standard treatments. First, patients receive a CAR-T cell therapy (engineered immune cells) followed by a stem cell transplant with high-dose chemotherapy. The …

This phase 2 trial is testing whether a two-year maintenance treatment with lenalidomide and rituximab can prevent relapse in patients with primary central nervous system lymphoma who have responded to initial chemotherapy but are not eligible for a stem cell transplant. The stud…

This study tests an experimental oral drug called emavusertib (CA-4948), taken alone or with ibrutinib, in adults with relapsed or refractory primary central nervous system lymphoma (PCNSL). The trial has multiple parts to find the safest dose and see if the drug shrinks tumors. …

This phase 2 trial tests a combination of three drugs—pomalidomide, tislelizumab, and selinexor—in 43 people with relapsed or refractory primary central nervous system lymphoma. The goal is to see if this cocktail can shrink tumors and improve survival. All participants receive t…

This early-stage trial tests a new oral drug called NX-2127 in adults with advanced B-cell cancers (like certain leukemias and lymphomas) that have not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to …

This study tests whether the drug acalabrutinib, taken as a pill, can safely prevent relapse in people with very high-risk large B-cell lymphoma after they receive cell therapy (stem cell transplant or CAR T-cells). The trial will enroll 24 adults aged 18-70. Researchers will tra…

This phase 2 trial is testing whether a combination of two drugs, zanubrutinib and pemetrexed, can safely control or shrink brain lymphomas that have come back or not responded to treatment. About 15 participants will receive the drugs in cycles, followed by maintenance therapy w…

This phase 1/2 trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to improve treatment for people with relapsed or refractory B-cell cancers like lymphoma and leukemia. The study will enroll up to 100 adults and eva…

This study is testing a combination of three drugs—pembrolizumab, ibrutinib, and rituximab—in people whose primary central nervous system lymphoma has returned or not responded to treatment. The goal is to see if the combination can stop the cancer from growing for at least 6 mon…

This pilot study tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy can safely treat newly diagnosed primary central nervous system lymphoma. The trial will enroll 15 adults and primarily look for serious side effects, while also checkin…

This study tests a combination of three drugs (thiotepa, pirtobrutinib, and sintilimab) for people with a type of brain lymphoma that has come back or is hard to treat. The goal is to see if this mix can shrink tumors and help patients live longer. About 24 adults will take part,…

This phase 2 trial is testing a combination of four drugs (PD-1 inhibitor, rituximab, methotrexate, and orelabrutinib) in 50 people with newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this mix can stop the cancer from growing for at least a yea…

This pilot study is testing a new treatment called Anbal-cel for people with relapsed or refractory primary or secondary central nervous system lymphoma. Anbal-cel is a CAR-T cell therapy made from the patient's own immune cells. The study will enroll 12 participants to see if th…

This early-stage study is testing a new immune cell therapy called CT1190B CAR-T in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells…

This early-stage trial is testing a new drug called Q702 in people with various blood cancers and related disorders that have not responded to standard treatments. Q702 is designed to help the immune system attack cancer cells and help the bone marrow make healthy blood cells. Th…

This study tests a combination of three drugs—orelabrutinib, selinexor, and a chemotherapy drug—in 25 people with relapsed or refractory central nervous system lymphoma, a type of brain cancer. The goal is to see if this mix can shrink tumors better than current treatments. Parti…

This study tests a three-drug combination (selinexor, methotrexate, and rituximab) in 30 adults with central nervous system lymphoma that has relapsed or not responded to treatment. The goal is to find the safest dose and see how well the combo works. Participants receive the dru…

This trial investigates whether a special MRI technique using hyperpolarized carbon-13 pyruvate can safely and effectively detect primary central nervous system lymphoma, a rare type of brain cancer. Participants receive an injection of the substance before an MRI scan, and resea…

This study follows people who previously received zamtocabtagene autoleucel, a CAR-T cell therapy for certain types of lymphoma. The goal is to monitor long-term health outcomes, including any new cancers, neurological issues, or autoimmune problems. By tracking participants over…

This study follows 100 adults with blood cancers (like lymphoma or leukemia) who receive whole brain radiation. Researchers will test memory, thinking, and quality of life over time using MRI scans and questionnaires. The goal is to understand how radiation affects the brain, not…

This study compares blood samples from 20 people with primary central nervous system lymphoma (a rare brain cancer) to samples from people with other types of lymphoma and healthy volunteers. Researchers will look at small molecules (metabolites) and immune cells to find differen…

This study follows 500 people who received CAR-T cells in earlier trials for blood cancers like lymphoma and multiple myeloma. Researchers will check for new cancers and track long-term safety and effectiveness over 15 years. No new treatment is given; it is purely an observation…